More

    Europe Markets

    Lenalidomide Mylan | European Medicines Agency (EMA)

    OverviewLenalidomide Mylan is a medicine used for the treatment of certain cancers affecting blood cells, namely multiple myeloma and follicular lymphoma.In multiple myeloma,...

    Joint strategy sets direction of EMA and EU medicines regulatory agencies to 2028

    The six focus areas of the strategy to 2028 build upon those in the EMANS to 2025 with the updated strategy placing more...

    Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva. It explains how the Agency assessed the medicine...

    Uptravi | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Uptravi. It explains how the Agency assessed the medicine to recommend...

    Skilarence | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Skilarence. It explains how the Agency assessed the medicine to recommend...

    Steglatro | European Medicines Agency (EMA)

    OverviewSteglatro is a medicine used to treat adults with type 2 diabetes together with diet and exercise.Steglatro can be used in combination with...

    Aerius | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Aerius. It explains how the Committee for Medicinal Products for Human...

    Azomyr | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Azomyr. It explains how the Committee for Medicinal Products for Human...

    Neoclarityn | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Neoclarityn. It explains how the Committee for Medicinal Products for Human...

    Benepali | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Benepali. It explains how the Agency assessed the medicine to recommend...

    Gencebok | European Medicines Agency (EMA)

    OverviewGencebok is a stimulant medicine used for treating apnoea of prematurity, a condition in which babies born prematurely stop breathing for longer than...

    Imcivree | European Medicines Agency (EMA)

    OverviewImcivree is a medicine used to treat obesity and help control hunger caused by certain genetic conditions that affect how the brain controls...

    Silodyx | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP)...

    Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 March 2025

    At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities, which cover all aspects of the risk management...

    First vaccine against epizootic haemorrhagic disease recommended for approval

    EMA has recommended the approval of Hepizovac, the first vaccine against epizootic haemorrhagic disease (EHD) authorised in the EU for use in cattle....

    Koselugo | European Medicines Agency (EMA)

    OverviewKoselugo is a medicine used to treat plexiform neurofibromas, benign (non-cancerous) tumours along the nerves, when they cause symptoms and cannot be removed...